How To Get A Fabulous Endometriosis Drugs Market On A Tight Budget
The
global endometriosis drugs market is expected to grow at a CAGR of 3.05% during
the forecast period. Some of the prominent vendors in the global endometriosis
drug market include AbbVie Inc., Allergan Plc, AstraZeneca Plc, Bayer AG,
Johnson & Johnson Services Inc., Mayne Pharma Group Ltd., Merck & Co.
Inc., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical
Industries Ltd., and among others.
There
have been multiple strategic alliances between vendors in the global
endometriosis drugs market in recent years. In June 2010, Neurocrine
Biosciences Inc. entered into an exclusive worldwide collaboration with AbbVie
to develop and commercialize elagolix for women’s and men’s health. In May
2018, Takeda and ASKA Pharmaceutical Co. Ltd. got into a partnership agreement.
In
January 2019, Debiopharm announced an agreement with Allergan to initiate a
transition process for TRELSTAR. Such strategic alliances are expected to help
overcome the challenges related to research and commercialization to provide
treatment to a large pool of patients. Hence, the increasing number of
strategic alliances is expected to contribute significantly to the growth of
the global endometriosis drugs market during the forecast period.
Comments
Post a Comment